CTLA4 and cancer: The Rothlin–Ghosh group tried several subcutaneously implanted cancer models, including the CTLA-4 and PD-1 checkpoint inhibitor-resistant YUMM1.7 and an orthotopic glioblastoma model in these mice [46].